Anticancer Drug Development, Breakthroughs are Waiting

New anticancer drug discovery, development and manufacture are entering into bottleneck stage at this moment. Many obstacles of biomedical, pharmaceutical, technology and economics lead to staggering pace of anticancer drug developments more recently. A declining successful rate of phase II and phase III anticancer drug evaluations is losing a great sum of money as well as human resource potentiality throughout the world. This editorial addresses some key factors affecting anticancer drug developments and providing possible avenues for drug development breakthroughs.